Last reviewed · How we verify
LY3819469
At a glance
| Generic name | LY3819469 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) (PHASE3)
- A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function (PHASE1)
- A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)] (PHASE2)
- A Study of LY3819469 in Participants With Impaired and Normal Renal Function (PHASE1)
- A Study to Compare Two Formulations of LY3819469 in Healthy Participants (PHASE1)
- A Study of LY3819469 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |